专利检索_ 转移含磷基团的转移酶专利检索_ 转移含磷基团的转移酶专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
1	用于制备3-羟基丙酸和其它产物的方法	CN201080053692.6	2010-09-27	CN102695799A	2012-09-26	M·D·林奇; R·T·吉尔; T·瓦内克-利普斯科布
本发明涉及经代谢工程改造的微生物菌株，如细菌菌株，其中对用于化学产物制备的丙二酰-CoA具有提高的利用率，所述化学产物包括3-羟基丙酸。
2	改善的NGS工艺流程	CN201580009710.3	2015-06-11	CN106715692A	2017-05-24	张锐; 梁诗婷; 萧若珊; 杨咏强; 阿西尼·史密诺夫; 朝楼平
本发明涉及允许从样品提取核酸，用于可以进行的下一代测序方法的DNA‑文库的PCR制备和PCR后制备的改善的半自动化方法。所述方法和与这些方法有关的其它方面为与非自动化的相应方法相比，需要较少的劳动力、安全成本、试剂并且较不易污染。
3	3−ヒドロキシプロピオン酸および他の生成物を生成するための方法	JP2015241185	2015-12-10	JP6271494B2	2018-01-31	マイケルディー. リンチ; ライアンティー. ギル; ターニャウォルネック−リプスコン

4	改善されたＮＧＳワークフロー	JP2016548175	2015-06-11	JP2017521356A	2017-08-03	チャン，ルイ; シー，レオン，ティン; ラフ，シオウ，サン; ヨン，ヨウ，チャン; スミルノフ，アルセニー; チャオ，ロウ，ピン
本発明は、実行可能な次世代シークエンシング法に対するサンプルからの核酸の抽出、PCRの調製、及びDNAライブラリのPCR後の作製工程を可能とする、改善された半自動化方法に関する。該方法及びかかる方法に関連する追加の態様は、自動化されていない類似の方法よりも、手間がかからず、安全性コストが安く、試薬が少なく、また汚染を生じにくい。【選択図】図1
5	Method for producing 3-hydroxypropionic acid and other products	US15167439	2016-05-27	US10100342B2	2018-10-16	Michael D Lynch; Ryan T. Gill; Tanya E. W. Lipscomb
This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a chemical product, which includes 3-hydroxypropionic acid.
6	DNA VECTORS, TRANSPOSONS AND TRANSPOSASES FOR EUKARYOTIC GENOME MODIFICATION	US15989124	2018-05-24	US20180258436A1	2018-09-13	Jeremy Minshull; Mark Welch; Sridhar Govindrajan; Maggie Lee; Kate Caves; Jon Ness
The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
7	DNA VECTORS, TRANSPOSONS AND TRANSPOSASES FOR EUKARYOTIC GENOME MODIFICATION	US15287622	2016-10-06	US20170101647A1	2017-04-13	Jeremy Minshull; Mark Welch; Sridhar Govindrajan; Maggie Lee; Kate Caves; Jon Ness
The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
8	WOUND HEALING	US14595755	2015-01-13	US20150190504A1	2015-07-09	STEPHEN M. GUNNIGLE
The present invention relates to the use of p38 MAP kinase inhibitors and p38 MAP kinase inhibition to promote wound healing.
9	METHODS FOR PRODUCING 3-HYDROXYPROPIONIC ACID AND OTHER PRODUCTS	US13498468	2010-09-27	US20130071893A1	2013-03-21	Michael D. Lynch; Ryan T. Gill; Tanya E.W. Lipscomb
This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a chemical product, which includes 3-hydroxypropionic acid.
10	Wound healing	US11574442	2005-08-31	US08063052B2	2011-11-22	Stephen M. Gunnigle
The present invention relates to the use of p38 MAP kinase inhibitors and p38 MAP kinase inhibition to promote wound healing.
11	カチオンキレーターホットスタート	JP2016548369	2015-01-15	JP2017504336A	2017-02-09	アレクサンダーアザウイ，; ラルフパイスト，
本発明は、核酸改変反応における酵素的活性の制御の分野におけるものである。本発明は、キレート剤の反応組成物への添加によって酵素的活性を制御する方法を記載し、二価カチオンのこれらのキレート剤への結合と一般的に使用される緩衝剤のpHとの両方が、温度依存性であるという事実を利用する。非特異的な副産物によって妨げられるPCR実験は制御され得、それにより、標的配列は、より特異的な様式で増幅される。核酸改変反応は、学究的背景と産業的背景との両方における現代の生物学的研究および薬学的研究において中心的な役割を担う。
12	Method for producing 3-hydroxypropionic acid and other products	JP2013056264	2013-03-19	JP2013128494A	2013-07-04	LYNCH MICHAEL D; GILL RYAN T; WARNECKE-LIPSCOMB TANYA
PROBLEM TO BE SOLVED: To provide a method for producing 3-hydroxypropionic acid and other products.SOLUTION: This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a chemical product, which includes 3- hydroxypropionic acid. In certain embodiments, the cell culture comprises an inhibitor of fatty acid synthase or the microorganism is genetically modified for reduced enzymatic activity in the organism's fatty acid synthase pathway. For example, the inhibitor of the fatty acid synthase may be selected from the group consisting of thiolactomycin, triclosan, cerulenin, thienodiazaborine, isoniazid, and analogs thereof.
13	A method for generating a 3-hydroxy-propionic acid and other products	JP2012531103	2010-09-27	JP2013505727A	2013-02-21	マイケルディー．リンチ，; ライアンティー．ギル，; ターニャウォルネック−リプスコン，
本発明は、３−ヒドロキシプロピオン酸を含む化学生成物の生成のためにマロニル−ＣｏＡの利用が増加している、細菌株などの代謝改変された微生物株に関する。ある特定の実施形態では、上記細胞培養物は、脂肪酸合成酵素の阻害剤を含むか、または上記微生物は、その微生物の脂肪酸合成酵素経路における酵素活性の低減のために遺伝子改変されている。例えば、上記脂肪酸合成酵素の阻害剤は、チオラクトマイシン、トリクロサン、セルレニン、チエノジアザボリン、イソニアジドおよびそれらの類似体からなる群から選択してよい。
14	ANTIBODIES TO ARGININOSUCCINATE SYNTHASE AND RELATED METHODS	EP15819121	2015-07-08	EP3166972A4	2018-01-31	HE WEI; GUO YUNYUN; WU BOR-WEN
Antibodies, and antigen-binding fragments, which specifically bind to argininosuccinate synthase, and related compositions, kits, and methods of use, which are useful as companion diagnostics to identify suitable subjects for arginine deprivation or depletion therapies such as ADI-PEG 20 and other arginine deiminase (ADI) polypeptide-based therapies.
15	３，６―안하이드로―Ｌ―갈락토오스를 대사하는 재조합 미생물 및 이의 용도	KR1020140054263	2014-05-07	KR101561390B1	2015-10-19	김경헌; 최인걸; 이세영; 윤은주; 김희택
본발명은 3,6-안하이드로-L-갈락토오스를대사하는재조합미생물및 이의용도에관한것으로, 보다상세하게는 3,6-AHG의대사경로에관여하는효소군을발현하는재조합미생물로부터에탄올을제조할수 있다.
16	VIRAL PARTICLE FOR THE TRANSFER OF RNAs, ESPECIALLY INTO CELLS INVOLVED IN IMMUNE RESPONSE	US16301354	2017-05-12	US20190203228A1	2019-07-04	Pascale BOUILLE; Christine DUTHOIT; Lucille LAMOUROUX
The present invention relates to retroviral particle comprising a protein derived from the Gag polyprotein, an envelope protein, optionally an integrase and at least two encapsidated non-viral RNAs, the encapsidated non-viral RNAs each comprising an RNA sequence of interest bound to an encapsidation sequence, each encapsidation sequence being recognized by a binding domain introduced into the protein derived from the Gag polyprotein and/or into the integrase, and at least one of said sequences of interest of the encapsidated non-viral RNAs comprises a part coding at least one epitope and/or at least one molecular structure specifically recognizing an epitope.
17	Antibodies to argininosuccinate synthase and related methods	US14794273	2015-07-08	US09938355B2	2018-04-10	Wei He; Yunyun Guo; Bor-Wen Wu
Antibodies, and antigen-binding fragments, which specifically bind to argininosuccinate synthase, and related compositions, kits, and methods of use, which are useful as companion diagnostics to identify suitable subjects for arginine deprivation or depletion therapies such as ADI-PEG 20 and other arginine deiminase (ADI) polypeptide-based therapies.
18	N-SUBSTITUTED 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE	US15504120	2015-08-27	US20170334886A1	2017-11-23	Gjalt W. Huisman; Jed Lee Hubbs; Xiyun Zhang; Robert Osborne
The present invention provides kinase inhibitor analogs with improved properties, such as improved efficacy, pharmacokinetics, safety, and specificity. In some embodiments, the present invention provides lapatinib analogs that provide therapeutic benefits.
19	MICROBIAL FERMENTATION OF ANHYDROSUGARS TO FATTY ACID ALKYL ESTERS	US15363043	2016-11-29	US20170175152A1	2017-06-22	Kelsey M. McNEELY; Virginia M. REINER
Methods are provided for biological conversion of anhydrosugars, such as anhydrosugars found in a pyrolysis oil, to fatty acid alkyl esters. The methods can include use of a genetically modified Escherichia coli (E. coli) bacteria that can convert levoglucosan and/or other anhydrosugars into fatty acid alkyl esters without requiring formation and conversion of an intermediate compound external to the bacteria. Optionally, the methods can be used in combination with methods for production and/or separation of increased amounts of levoglucosan from pyrolysis of biomass.
20	Recombinant microorganism metabolizing 3,6-anhydride-L-galactose and a use thereof	US14889376	2014-05-07	US09637761B2	2017-05-02	Kyoung Heon Kim; In-Geol Choi; Eun-Ju Yun; Sae Young Lee; Hee Taek Kim
The present invention relates to a recombinant microorganism metabolizing 3,6-anhydro-L-galactose and a use thereof, and, more particularly, can produce ethanol from a recombinant microorganism expressing an enzyme group involved in a metabolic pathway of 3,6-AHG.

1 2 3

该功能需要专业版企业版VIP权限，您可以：